重组人脑利钠肽联合地高辛治疗扩张型心肌病心力衰竭患者的临床疗效  

Clinical efficacy of recombinant human brain natriuretic peptide combined with digoxin in the treatment of patients with dilated cardiomyopathy and heart failure

作　　者：冯小倩[1] FENG Xiaoqian(Department of Cardiovascular Medicine,Guangzhou Twelfth People's Hospital of,Guangzhou,Guangdong,510620,China)

机构地区：[1]广州市第十二人民医院心血管内科,广东广州510620

出　　处：《当代医学》2023年第36期127-130,共4页Contemporary Medicine

摘　　要：目的探讨重组人脑利钠肽联合地高辛治疗扩张型心肌病心力衰竭患者的临床疗效。方法选取2018年4月2021年4月于广州市第十二人民医院进行治疗的83例扩张型心肌病心力衰竭患者作为研究对象,采用随机信封法分为对照组(n=41)与研究组(n=42)。对照组给予口服地高辛治疗,研究组给予重组人脑利钠肽联合地高辛治疗,比较两组治疗前后血浆N-末端B型脑钠肽前体(NT-proBNP)水平、心功能指标、血管内皮功能指标及临床疗效。结果治疗后,两组血浆NT-proBNP水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后,研究组左心室射血分数(LVEF)、心脏指数(CI)均高于治疗前和对照组,每搏量(SV)、心输出量(CO)均大于治疗前和对照组,差异有统计学意义(P<0.05)。治疗后,两组肱动脉内皮依赖性舒张功能(FMD)均高于治疗前,血清一氧化氮(NO)水平均低于治疗前,研究组血清内皮素-1(ET-1)水平低于治疗前,且研究组肱动脉FMD、血清NO水平均高于对照组,血清ET-1水平低于对照组,差异有统计学意义(P<0.05);对照组治疗前后血清ET-1水平比较差异无统计学意义。研究组治疗总有效率为95.24%,明显高于对照组的75.61%,差异有统计学意义(P<0.05)。结论重组人脑利钠肽联合地高辛治疗扩张型心肌病心力衰竭疗效显著,可有效改善患者心功能,降低血浆NT-proBNP水平,改善血管内皮功能指标,具有较高的临床应用价值。Objective To investigate the clinical efficacy of recombinant human brain natriuretic peptide combined with digoxin in the treatment of patients with dilated cardiomyopathy and heart failure.Methods 83 patients with dilated cardiomyopathy and heart failure treated in the Guang-zhou Twelfth People's Hospital from April 2018 to April 2021 were selected as the study subjects,and they were divided into the control group(n=41)and the study group(n=42)by random envelope method.The control group was given oral digoxin,and the study group was given recombinant human brain natriuretic peptide combined with digoxin,the plasma N-terminal pro-brain natriuretic peptide(NT-proBNP)levels,cardiac function,vascular endothelial function before and after the treatment and clinical efficacy were compared between the two groups.Results After treatment,the level of plasma NT-proBNP of the two groups was lower than that before treatment,and the study group was lower than the control group,the dif-ference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)and cardiac index(CI)in the study group were higher than those before treatment and the control group,stroke volume(SV)and cardiac output(CO)were higher than those before treatment and the control group,and the differences were statistically significant(P<0.05).After treatment,brachial artery flow-mediated dilation(FMD)of the two groups were higher than before treatment,serum nitric oxide(NO)level were lower than before treatment,and serum endothelin-1(ET-1)level in the study group was lower than before treatment,the brachial artery FMD and serum NO levels in the study group were higher than those in the control group,and the serum ET-1 level was lower than that in the control group,and the differences were statistically significant(P<0.05);there was no sig-nificant difference in serum ET-1 level in the control group before and after treatment.The total effective rate in the study group was 95.24%,which was higher than 75.61%in the control

关 键 词：重组人脑利钠肽 地高辛 扩张型心肌病 心力衰竭 心功能 

分 类 号：R541.6[医药卫生—心血管疾病] R542.2[医药卫生—内科学]